Page last updated: 2024-12-10

kuwanon h

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kuwanon H: a non-peptide bombesin receptor antagonist; RN refers to (1S-(1alpha,5alpha,6beta))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

kuwanone H : A tetrahydroxyflavone isolated from the plant species of the genus Morus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281668
CHEMBL ID506234
CHEBI ID6147
SCHEMBL ID150578
MeSH IDM0250709

Synonyms (27)

Synonym
gtpl622
kuwanone h
76472-87-2
kuwanon h
chebi:6147 ,
CHEMBL506234
kumanon h
8-[6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one
4h-1-benzopyran-4-one, 8-(6-(2,4-dihydroxy-3-(3-methyl-2-butenyl )benzoyl)-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methyl-2-butenyl)-, (1s-(1alpha,5alpha,6beta))-
nsc 356889
8-[(1s,5r,6s)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one
8-[(1s,5r,6s)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-1-cyclohex-2-enyl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one
SCHEMBL150578
8-{(1r,2s,3s)-2-[2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]-2',4'-dihydroxy-5-methyl[1,2,3,6-tetrahydro[1,1'-biphenyl]]-3-yl}-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-en-1-yl)-4h-1-benzopyran-4-one
moracenin a
8-((1r,2s,3s)-2-(2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)benzoyl)-2',4'-dihydroxy-5-methyl-1,2,3,6-tetrahydro-[1,1'-biphenyl]-3-yl)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-en-1-yl)-4h-chromen-4-one
AKOS037515236
CS-0023002
HY-N2600
MS-31352
DTXSID301318627
kuwanonh
2-(2,4-bis(oxidanyl)phenyl)-8-((1s,5s,6r)-5-(2,4-bis(oxidanyl)phenyl)-3-methyl-6-(3-(3-methylbut-2-enyl)-2,4-bis(oxidanyl)phenyl)carbonyl-cyclohex-2-en-1-yl)-3-(3-methylbut-2-enyl)-5,7-bis(oxidanyl)chromen-4-one
4h-1-benzopyran-4-one, 8-[6-[2,4-dihydroxy-3-(3-methyl-2-butenyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methyl-2-butenyl)-, [1s-(1alpha,5alpha,6beta)]-
4h-1-benzopyran-4-one, 8-[(1s,5r,6s)-6-[2,4-dihydroxy-3-(3-methyl-2-buten-1-yl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methyl-2-buten-1-yl)-
8-[(1s,5r,6s)-6-[2,4-dihydroxy-3-(3-methyl-2-buten-1-yl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methyl-2-buten-1-yl)-4h-1-benzopyran-4-one
822Q5M4B5D

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID332856Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets
AID332860Stimulation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets at 1 mM
AID332851Stimulation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets at 10 uM
AID332853Stimulation of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets
AID332858Inhibition of thromboxane B2 formation in Wistar King platelets
AID1346497Rat BB1 receptor (Bombesin receptors)1995Biochemical and biophysical research communications, Aug-15, Volume: 213, Issue:2
Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry.
AID1346516Mouse BB2 receptor (Bombesin receptors)1995Biochemical and biophysical research communications, Aug-15, Volume: 213, Issue:2
Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.62 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]